Gustavo Heresi-Davila, MD

• CTEPH Subcommittee of PHA's Early Diagnosis Campaign

  Member2014 – Present

• American Thoracic Society Assembly on Pulmonary Circulation Program Committee

  Member2015 – present

• Editorial Board member for CTEPH.com.

  Member 2014 – Present

• Writing Committee of the ISHLT Consensus Document titled“Consensus Statement: The Evaluation and Management of Patients with Chronic Thromboembolic Pulmonary Hypertension”

  Member2017

• Pulmonary Embolism Response Team (PERT) Consortium Research Committee

  Co-Chair 2018

• PHA Scientific Leadership Council CTEPH Working Group

  Member May 2018 - Present

• Master of Science in Clinical Research Program at Case Western Reserve University

• Gilead Sciences Research Scholars Program Award in Pulmonary Arterial Hypertension 2009
• Listed in Who's Who in America 2009
• Listed in Best Doctors in America 2012
• Young Investigator Award, American College of Chest Physicians 2012
• Teacher of the Year Award, Cleveland Clinic Pulmonary/Critical Care Fellowship Program 2013-2014

See publications for this provider. (Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)

Cleveland Clinic physicians and scientists collaborate with industry to advance medical breakthroughs. These partnerships help commercialize discoveries for public benefit while maintaining scientific integrity. To ensure transparency and minimize potential bias, Cleveland Clinic reviews these relationships and publicly discloses when physicians/scientists receive significant compensation for consulting, serve in fiduciary roles, receive royalties, or hold equity interests related to their work. We manage potential conflicts through approval processes, annual reporting, and targeted management plans.

As of 2025-06-20, Dr. Heresi-Davila has reported the financial relationships with the companies listed below.

Consulting and/or Speaking. Dr. Heresi-Davila receives fees of $5,000 or more per year (or, in rare cases, equity or stock options) as a paid consultant, speaker or as a member of an advisory committee for the following companies:

• Merck & Co., Inc.

Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers' discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias.

* Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.